Delayed behavioral effects following intrahippocampal injection of aggregated Aβ((1-42))

Brain Research

Volumn 815, Issue 1, 1999, Pages 1-10

  O'Hare, E ^a,b,e   Weldon, D T ^c   Mantyh, P W ^b   Ghilardi, J R ^b   Finke, M P ^b   Kuskowski, M A ^a   Maggio, J E ^d   Shephard, R A ^e   Cleary, J ^a,b  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

^c UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^d UNIVERSITY OF CINCINNATI   (United States)

^e UNIVERSITY OF ULSTER   (United Kingdom)

Author keywords

Behavior; Beta amyloid; Learning

Indexed keywords

AMYLOID BETA PROTEIN;

ALZHEIMER DISEASE; ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL ACTIVATION; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; GLIA CELL; HIPPOCAMPUS; MALE; NONHUMAN; PATHOPHYSIOLOGY; PERSEVERATION; PRIORITY JOURNAL; PROTEIN AGGREGATION; RAT; TASK PERFORMANCE;

AMYLOID BETA-PROTEIN; ANIMALS; BEHAVIOR, ANIMAL; BRAIN CHEMISTRY; CONDITIONING (PSYCHOLOGY); HIPPOCAMPUS; MALE; MICROINJECTIONS; PEPTIDE FRAGMENTS; RATS; RATS, SPRAGUE-DAWLEY; TIME FACTORS;

EID: 0033514079     PISSN: 00068993     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-8993(98)01002-6     Document Type: Article

References (76)

1. Araujo D.M., Cotman C.W. β-amyloid stimulates glial cells in vitro to produce growth factors that accumulate in senile plaques in Alzheimer's disease. Brain Res. 569:1992;141-145.
2. Busciglio J., Lorenzo A., Yeh J., Yankner B.A. β-amyloid fibrils induce tau phosphorylation and loss of microtubule binding. Neuron. 14:1995;879-888.
3. Busciglio J., Lorenzo A., Yankner B.A. Methodological variables in the assessment of β-amyloid neurotoxicity. Neurobiol. Aging. 13:1992;609-612.
4. Canning D.R., McKeon R.J., DeWitt D.A., Perry G., Wujek J.R., Frederickson R.C., Silver J. β-amyloid of Alzheimer's disease induces reactive gliosis that inhibits axonal outgrowth. Exp. Neurol. 124:1993;289-298.
5. Carlton P.L. Some effects of scopolamine, atropine and amphetamine in three behavioral situations. Pharmacologist. 3:1961;60.
6. Cleary J., Hittner J.M., Semotuk M.T., Mantyh P.W., O'Hare E. β-amyloid (1-40) effects on behavior and memory. Brain Res. 682:1995;69-74.
7. Chase N.T., Foster N.L., Fedio P., Brooks R., Mansi L., Di Chiro G. Regional cortical dysfunction in Alzheimer's disease as determined by positron emission tomography. Ann. Neurol. 15:1984;S170-S174.
8. Chen S.-Y., Wright J.W., Barnes C.D. The neurochemical and behavioral effects of β-amyloid peptide (25-35). Brain Res. 720:1996;54-60.
9. Citron M., Oltersdorf T., Haas C., McConlogue L., Hung A.Y., Seubert P., Vigo-Pelfrey C., Leiberburg I., Selkoe D.J. Mutation of the beta-amyloid precursor protein in familial Alzheimer's disease increases beta-protein production. Nature. 360:1992;672-674.
10. Cole G.M., Frautschy S.A. Animal models for Alzheimer's disease. Alzheimer's Disease Review. 2:1997;2-10.
11. Cotman C.W., Anderson A.J. A potential role for apoptosis in neurodegeneration in Alzheimer's disease. Mol. Neurobiol. 10:1995;19.
12. Cummings B.J., Cotman C.W. Image analysis of beta-amyloid load in Alzheimer's disease and relation to dementia severity. Lancet. 346:1995;1524-1528.
13. Delobette S., Privat A., Maurice T. In vitro aggregation facilitates β-amyloid peptide-(25-35)-induced amnesia in the rat. Eur. J. Pharmacol. 319:1997;1-4.
14. Dickson D.W., Lee S.C., Mattiace L.A., Yen S.H., Brosnan C. Microglia and cytokines in neurological disease, with special reference to AIDS and Alzheimer's disease. Glia. 7:1993;75-83.
15. Dornan W.A., Kang D.E., McCampbell A., Kang E.E. Bilateral injections of βA(25-35)+IBO into the hippocampus disrupts acquisition of spatial learning in the rat. NeuroReport. 5:1993;165-168.
16. Duffy P.E., Rapoport S.I., Graf L. Glial fibrillary acidic protein and Alzheimer's-type senile dementia. Neurology. 30:1980;778-782.
17. Esler W.P., Stimson E.R., Ghilardi J.R., Felix A.M., Lu Y., Vinters H.V., Mantyh P.W., Maggio J.E. A-beta deposition inhibitor screen using synthetic amyloid. Nat. Biotech. 15:1997;258-263.
18. Ettinger R.H., Staddon J.E.R. Decreased feeding associated with acute hypoxia in rats. Physiol. Behav. 29:1982;455-458.
19. Ettinger R.H., Staddon J.E.R. Operant regulation of feeding: a static analysis. Behav. Neurosci. 97:1993;639-653.
20. Ettinger R.H., Thompson S., Staddon J.E.R. Cholecystokinin, diet palatability and feeding regulation in rats. Physiol. Behav. 36:1986;801-809.
21. Feldon M., Lyon D.O. The post-reinforcement pause. J. Exp. Anal. Behav. 9:1966;131-134.
22. Flood J.F., Morley J.E., Roberts E. Amnesic effects in mice of four synthetic peptides homologous to amyloid beta protein from patients with Alzheimer's disease. Proc. Natl. Acad. Sci. U.S.A. 88:1991;3363-3366.
23. Frautschy S.A., Baird A., Cole G.M. Effects of injected Alzheimer β-amyloid cores in rat brain. Proc. Natl. Acad. Sci. U.S.A. 88:1991;8362-8366.
24. Frautschy S.A., Yang F., Calderon L., Cole G.M. Rodent models of Alzheimer's disease: rat Aβ infusion approaches to amyloid deposits. Neurobiol. Aging. 17:1996;311-321.
25. Games D., Adams D., Alessandrini R., Barbour R., Berthelette P., Blackwell C., Carr T., Clemens J., Donaldson T., Gillespie F., Guido T., Hagoplan S., Johnson-Wood K., Khan K., Lee M., Leibowitz P., Leiberburg I., Little S., Masliah E., McConlogue L., Monyoya-Zavala M., Mucke L., Paganini L., Penniman E., Power M., Schenk D., Seubert P., Snyder B., Soriano F., Tan H., Vitale J., Wadsworth S., Wolozin B., Zhao J. Alzheimer's-type neuropathology in transgenic mice overexpressing V717F β-amyloid precursor protein. Nature. 373:1995;523-527.
26. Giaccone G., Tagliavini F., Linoli G., Bouras C., Frigerio L., Frangione B., Bugiani O. Down's patients: extracellular preamyloid deposits precede neuritic degeneration and senile plaques. Neurosci. Lett. 97:1989;232-238.
27. Giovannelli L., Casamenti F., Scaki C., Bartolini L., Pepeu G. Differential effects of amyloid peptides β-(1-40) and β-(25-35) injections into the rat nucleus basalis. Neuroscience. 66:1995;781-792.
28. Glenner G.G., Wong C.W. Alzheimer's disease and Down's syndrome: sharing of a unique cerebrovascular amyloid fibril protein. Biochem. Biophys. Res. Commun. 122:1984;1.
29. Goate A., Chartier-Harlin M.C., Mullan M., Brown J., Crawford F., Fidani L., Giuffra L., Haynes A., Irving N., James L., Manti R., Newton P., Rooke K., Roques P., Talbot C., Pericak-Vance M., Roses A., Williamson R., Rossor M., Owen M., Hardy J. Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer's disease. Nature. 349:1991;704-705.
30. Goldgaber D., Lerman M., McBride O., Saffiot U., Gadjusek D. Characterization and chromosomal location of cDNA encoding brain amyloid of Alzheimer's disease. Science. 235:1987;877-880.
31. Haga S., Akai K., Ishii T. Demonstration of microglial cells in and around senile (neuritic) plaques in the Alzheimer brain. An immunohistochemical study using a novel monoclonal antibody. Acta Neuropathol. 77:1989;569-575.
32. Hansen L.A., Armstrong D.M., Terry R.D. An immunohistochemical quantification of fibrous astrocytes in the aging human cerebral cortex. Neurobiol. Aging. 8:1987;1-6.
33. Hatten M.E., Leim R.K., Shelanski M.L., Mason C.A. Astroglia in CNS injury. Glia. 4:1991;233-243.
34. Hoke A., Canning D.R., Malemud C.J., Silver J. Regional differences in reactive gliosis induced by substrate-bound β-amyloid. Exp. Neurol. 130:1994;56-66.
35. Howlett D.R., Jennings K.H., Lee D.C., Clark M.S., Brown F., Wetzel R., Woods S.J., Camilleri P., Roberts G.W. Aggregation state and neurotoxic properties of Alzheimer β-amyloid peptide. Neurodegeneration. 4:1995;23-32.
36. Hsaio K., Chapman P., Nilsen S., Eckman C., Harigaya Y., Younkin S., Yang F., Cole G. Correlative memory deficits, Aβ elevation, and amyloid plaques in transgenic mice. Science. 274:1996;99-103.
37. Itagaki S., Megeer P.L., Akiyama H., Zhu S., Selkoe D. Relationship of microglia and astrocytes to amyloid deposits of Alzheimer's disease. J. Neuroimmunol. 24:1989;173-182.
38. Jarrett J.T., Berger E.P., Lansbury P.T. Jr. The carboxy terminus of the β-amyloid protein is critical for the seeding of amyloid formation: implications for the pathogenesis of Alzheimer's disease. Biochemistry. 32:1993;4693-4697.
39. Kang J., Lemaire H.G., Unterbeck A., Salbaum J.M., Masters C.L., Crzesckik K.H., Multhaup G., Beyreuther K., Muller-Hill B. The precursor of Alzheimer's disease amyloid A4 protein resembles a cell-surface receptor. Nature. 325:1987;733-734.
40. Kowall N.W., Beal M.F., Busciglio J., Duffy L.K., Yankner B.A. An in vivo model for the neurodegenerative effects of β-amyloid and protection by substance P. Proc. Natl. Acad. Sci. U.S.A. 88:1991;7247-7251.
41. Kowall N.W., McKee A.C., Yankner B.A., Beal M.F. In vivo neurotoxicity of β-amyloid β (1-40) and the β (25-35) fragment. Neurobiol. Aging. 13:1992;537-542.
42. Lorenzo A., Yankner B.A. β-amyloid neurotoxicity requires fibril formation and is inhibited by congo red. Proc. Natl. Acad. Sci U.S.A. 91:1994;12243-12247.
43. Malouf A.T. Effect of beta amyloid peptides on neurons in hippocampal slice cultures. Neurobiol. Aging. 13:1992;543-551.
44. Mann D.M., Yates P.O., Marcyniuk B., Ravindra C.R. The topography of plaques and tangles in Down's syndrome patients of different ages. Neuropathol. Appl. Neurobiol. 12:1986;447-457.
45. Mattson M.P., Tomaselli K.J., Rydel R.E. Calcium-destabilizing and neurodegenerative effects of aggregated β-amyloid peptide are attenuated by basic FGF. Brain Res. 621:1993;35-49.
46. Maurice T., Lockhart B.P., Privat A. Amnesia induced in mice by centrally administered β-amyloid peptides involves cholinergic dysfunction. Brain Res. 706:1996;181-193.
47. May P.C., Gitter B.D., Waters D.C., Simmons L.K., Becker G.W., Small J.S., Robinson P.M. Beta-amyloid peptide in vitro toxicity: lot to lot variability. Neurobiol. Aging. 13:1992;605-607.
48. McDonald M.P., Dahl E.E., Overmier J.B., Mantyh P.W., Cleary J. Effects of an exogenous β-amyloid peptide on retention for spatial learning. Behav. Neural Biol. 62:1994;60-67.
49. McDonald M.P., Overmier J.B., Bandyopadhyay S., Babcock D., Cleary J. Reversal of β-amyloid-induced deficit after exposure to training and state cues. Neurobiol. Learn. Mem. 65:1996;35-47.
50. McGeer P.L., Rogers J., McGeer E.G. Neuroimmune mechanisms in Alzheimer's disease pathogenesis. Alzheimer Dis. Assoc. Disord. 8:1994;149-158.
51. Meunier G.F., Starratt C., Sergio J. Quantification of pausing on fixed-ratio schedules of reinforcement. Bull. Psychonom. Soc. 14:1979;340-342.
52. Nabeshima T., Nita A. A memory impairment and neuronal dysfunction induced by β-amyloid protein in rats. Tohoku J. Exp. Med. 174:1994;241-249.
53. O'Hare E., Levine A.S., Semotuk M.T., Tierney K.J., Shephard R.A., Grace M.K., Cleary J. Utilization of a novel model of food reinforced behavior involving neuropeptide Y, insulin, 2-deoxy-D-glucose and naloxone. Behav. Pharmacol. 7:1996;742-753.
54. Pearson R.C.A., Powell T.P.S. The neuroanatomy of Alzheimer's disease. Rev. Neurosci. 2:1989;101-122.
55. Pike C.J., Burdick D., Walencewicz A.J., Glabe C.J., Cotman C.W. Neurodegeneration induced by β-amyloid peptides in vitro: the role of peptide assembly state. J. Neurosci. 13:1993;1676-1687.
56. Pike C.J., Cummings B.J., Monzavi R., Cotman C.W. β-amyloid induced changes in cultured astrocytes parallel reactive astrocytosis associated with senile plaques in Alzheimer's disease. Neuroscience. 63:1994;517-531.
57. Pike C.J., Walencewicz A.J., Glabe C.G., Cotman C.W. Aggregation-related toxicity of synthetic β-amyloid protein in hippocampal cultures. Eur. J. Pharmacol. 207:1991;367-368.
58. Powell R.W. The effects of small sequential changes in fixed-ratio size upon the post-reinforcement pause. J. Exp. Anal. Behav. 11:1968;589-593.
59. Roher A.E., Ball M.J., Bhave S.V., Wakade A.R. β-amyloid from Alzheimer disease brains inhibits sprouting and survival of sympathetic neurons. Biochem. Biophys. Res. Commun. 174:1991;572-579.
60. Rumble B., Retallack R., Hilbich C., Simms G., Malthaup G., Martins R., Montogmery P., Beyreuther K., Masters C.L. Amyloid A4 protein and its precursor in Down's syndrome and Alzheimer's disease. New Engl. J. Med. 320:1989;1446-1452.
61. Selkoe D.J. Alzheimer's disease: a central role for amyloid. J. Neuropathol. Exp. Neurol. 53:1994;438-447.
62. Sheng G.K., Mrak R.E., Griffin W.S. Microglial interleukin-1 alpha expression in brain regions in Alzheimer's disease: correlation with neuritic plaque distribution. Neuropathol. Appl. Neurobiol. 21:1995;290-301.
63. Sigurdsson E.M., Hejna M.J., Lee J.M., Lorens S.A. β-amyloid 25-35 and/or quinolinic acid injections into the basal forebrain of young male Fischer-344 rats: behavioral, neurochemical and histological effects. Behav. Brain Res. 72:1995;141-156.
64. Sigurdsson E.M., Lee J.M., Dong X.W., Hejna M.J., Lorens S.A. Bilateral injections of amyloid-β 25-35 into the amygdala of young fischer rats: behavioral, neurochemical, and time dependent histopathological effects. Neurobiol. Aging. 18:1997;591-608.
65. Sigurdsson E.M., Lee J.M., Dong X.W., Hejna M.J., Lorens S.A. Laterality in the histological effects of injections of amyloid-β 25-35 into the amygdala of young Fischer rats. J. Neuropathol. Exp. Neurol. 56:1997;714-726.
66. Sigurdsson E.M., Lorens S.A., Hejna M.J., Dong X.W., Lee J.M. Local and distant histopathological effects of unilateral amyloid-β 25-35 injections into the amygdala of young F344 rats. Neurobiol. Aging. 17:1996;893-901.
67. Snow A.D., Sekiguchi R., Nochlin D., Fraser P., Kimata K., Mizutani A., Arai M., Schreier A., Morgan D.G. An important role of heparin sulfate proteoglycan (Perlecan) an a model system for the deposition and persistence of fibrillar Aβ-amyloid in rat brain. Neuron. 12:1994;219-234.
68. Tate B., Aboody-Guterman K.S., Morris A.M., Walcot E.C., Majocha R.E., Marotta C.A. Disruption of circadian regulation by brain grafts that overexpress Alzheimer β/A4 amyloid. Proc. Natl. Acad. Sci. U.S.A. 89:1992;7090-7094.
69. P.F. Vellman, D.C. Hoaglin, Applications, Basics, and Computing of Exploratory Data Analysis, Duxbury Press, Boston, MA, 1981, p. 171.
70. Weldon D.T., O'Hare E., Kuskowski M.A., Cleary J., Mach J.R. Alternating lever cyclic-ratio schedule analysis of the effects of atropine sulfate. Pharmacol. Biochem. Behav. 54:1995;753-757.
71. Weldon D.T., Rogers S.D., Ghilardi J.R., Finke M.P., Cleary J.P., O'Hare E., Esler W.P., Maggio J.E., Mantyh P.W. Fibrillar β-amyloid induces microglial phagocytosis, expression of inducible nitric oxide synthase, and loss of a select population of neurons in the rat CNS in vivo. J. Neurosci. 18:1998;2161-2173.
72. Winkler J., Connor D.J., Frautschy S.A., Behl C., Waite J.J., Cole G.M., Thal L.J. Lack of long-term effects after β-amyloid protein injections in rat brain. Neurobiol. Aging. 15:1994;601-607.
73. Wisniewski K.E., Wisniewski H.M., Wen G.Y. Occurrence of neuropathological changes and dementia of Alzheimer's disease in Down's syndrome. Ann. Neurol. 17:1985;278-282.
74. Yankner B.A., Caceres A., Duffy L.K. Nerve growth factor potentiates the neurotoxicity of β-amyloid. Proc. Natl. Acad. Sci. U.S.A. 87:1990;9020-9023.
75. Yankner B.A., Dawes L.R., Fisher S., Villa-Komaroff L., Oster-Granite M.L. Neurotoxicity of a fragment of the amyloid precursor associated with Alzheimer's disease. Science. 245:1989;417-420.
76. Yanker B.A., Duffy L.K., Kirschner D.A. Neurotrophic and neurotoxic effects of amyloid β-protein: reversal by tachykinin neuropeptides. Science. 250:1990;279-282.